According to data from S&P Global Market Intelligence, shares of the leading RNA interference drugmaker Alnylam Pharmaceuticals (NASDAQ: ALNY) gained 18.5% last month. The biotech's stock was lifted up by both the insurgent victory of Donald Trump -- presumably because of his less vitriolic stance on U.S. drug pricing schemes than Hillary Clinton -- along with Sanofi's (NYSE: SNY) decision to opt-in to co-develop and co-commercialize the experimental hemophilia treatment fitusiran in the United States, Canada, and Western Europe.Prior to last month's rally, Alnylam's stock was in a tailspin as a result of its decision to discontinue the development of the late-stage hereditary ATTR amyloidosis drug candidate revusiran.